Lovastatin and rosuvastatin were the top‐ranked compounds negatively enriched in GATA3‐low tumors (supplementary material, Table S9), indicating a potential relevance for HMGCR inhibitors to GATA3‐low BC. Here, HMGCR is linked to breast cancer.